Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041582 | PMC |
| http://dx.doi.org/10.1128/JCM.01627-19 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Predispositions, Features, and Outcomes of Infections with Carbapenem-resistant among Critical Care Patients.
Indian J Crit Care Med
January 2025
Department of Critical Care, Faculty of Medicine, Cairo University, Cairo, Egypt.
Background: Carbapenem-resistant (CRE) infections pose a significant global public health threat. We aimed to assess the risk variables, clinical characteristics, and outcomes of CRE-caused infections in criticalcare patients.
Patients And Methods: This prospective study enrolled 181 adult patients infected with in the intensive care unit (ICU).
A novel approach to antimicrobial resistance: Machine learning predictions for carbapenem-resistant Klebsiella in intensive care units.
Int J Med Inform
December 2024
Department of Anaesthesiology and Reanimation, University of Kocaeli, Kocaeli, Turkey.
This study was conducted at Kocaeli University Hospital in Turkey and aimed to predict carbapenem-resistant Klebsiella pneumoniae infection in intensive care units using the Extreme Gradient Boosting (XGBoost) algorithm, a form of artificial intelligence. This was a retrospective case-control study involving 289 patients, including 159 carbapenem-resistant and 130 carbapenem-susceptible individuals as controls. The model's predictive analysis combined a diverse range of demographic, clinical, and laboratory data, resulting in an average accuracy of 83.
View Article and Find Full Text PDFBacteremic nosocomial pneumonia caused by Gram-negative bacilli: results from the nationwide ALARICO study in Italy.
Infection
December 2024
Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Pisana, University of Pisa, Pisa, Italy.
Purpose: To describe the clinical characteristics and outcomes of patients with nosocomial pneumonia (NP) caused by carbapenem-resistant Gram-negative bacilli (CR-GNB) and to compare them to patients with NP caused by carbapenem-susceptible (CS)-GNB.
Methods: Prospective observational multicenter study including patients with bacteremic NP caused by GNB from the ALARICO Network (June 2018-January 2020). The primary outcome measure was 30-day mortality.
Development of prediction models for carbapenem-resistant acquisition and prognosis in adult patients.
Front Pharmacol
November 2024
Department of Pharmacy, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Article Synopsis
- The study aimed to investigate the risk factors and clinical outcomes of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in adult patients and create a predictive nomogram for infection and mortality risks.
- Data was collected from 467 patients, revealing that CRKP infection was linked to factors such as high comorbidity scores, use of central venous catheters, recent hospitalizations, and prior antibiotic exposure.
- The resulting nomogram demonstrated strong predictive capabilities for CRKP infection and indicated that older age, severe comorbidity, and certain clinical conditions increased the likelihood of 30-day mortality.
Mutant prevention concentrations, resistance evolution dynamics, and mechanisms of resistance to imipenem and imipenem/relebactam in carbapenem-susceptible isolates showing ceftazidime/avibactam resistance.
Antimicrob Agents Chemother
December 2024
Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.
carbapenemase (KPC) variants selected during ceftazidime/avibactam treatment usually develop susceptibility to carbapenems and carbapenem/β-lactamase inhibitors, such as imipenem and imipenem/relebactam. We analyzed imipenem and imipenem/relebactam single-step mutant frequencies, resistance development trajectories and differentially selected resistance mechanisms using two representative isolates that had developed ceftazidime/avibactam resistance during therapy (ST512/KPC-31 and ST258/KPC-35). Mutant frequencies and mutant prevention concentrations were measured in Mueller-Hinton agar plates containing incremental concentrations of imipenem or imipenem/relebactam.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!